|
Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C). |
|
|
Honoraria - Astellas Pharma; Sanofi |
Consulting or Advisory Role - Lilly; MSD; Roche Pharma AG; Sanofi |
Travel, Accommodations, Expenses - Janssen; Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Janssen; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Millennium; Novartis; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Janssen; Sanofi |